faculty_name,faculty_email,publication_type,title,journal,year,doi,url,file_created
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant.",British Journal of Cancer,2025,10.1038/s41416-025-03029-x,https://experts.mcmaster.ca/display/publication3579522,2025-07-27T15:01:37.354052
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Bilateral oophorectomy and the probability of amnestic mild cognitive impairment among carriers of a pathogenic variant in BRCA1 or BRCA2.,International Journal of Gynecological Cancer,2025,10.1016/j.ijgc.2025.101929,https://experts.mcmaster.ca/display/publication3590654,2025-07-27T15:01:37.354059
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Bilateral Oophorectomy And The Probability Of Amnestic Mild Cognitive Impairment Among Carriers Of A Pathogenic Variant In BRCA1 Or BRCA2,International Journal of Gynecological Cancer,2025,10.1016/j.ijgc.2024.100379,https://experts.mcmaster.ca/display/publication3554532,2025-07-27T15:01:37.354061
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation.,Cancer,2025,10.1002/cncr.35666,https://experts.mcmaster.ca/display/publication3492443,2025-07-27T15:01:37.354063
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Patient Characteristics and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Patients- a Multicenter Canadian Study,Blood,2024,10.1182/blood-2024-200297,https://experts.mcmaster.ca/display/publication3504730,2025-07-27T15:01:37.354064
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Incidence of endometrial cancer in BRCA mutation carriers.,Gynecologic Oncology,2024,10.1016/j.ygyno.2024.07.687,https://experts.mcmaster.ca/display/publication3464343,2025-07-27T15:01:37.354066
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN),Annals of Oncology,2024,10.1016/j.annonc.2024.08.2276,https://experts.mcmaster.ca/display/publication3472586,2025-07-27T15:01:37.354068
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Iterative qualitative approach to establishing content validation of a  patient-reported outcome measure for arm lymphedema: the LYMPH-Q Upper Extremity Module,Journal of Patient-Reported Outcomes,2024,10.1186/s41687-024-00701-3,https://experts.mcmaster.ca/display/publication3447911,2025-07-27T15:01:37.354069
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations,Hereditary Cancer in Clinical Practice,2024,10.1186/s13053-024-00277-5,https://experts.mcmaster.ca/display/publication3431302,2025-07-27T15:01:37.354071
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Acute Toxicity Results from the Randomized Assessment of Cisplatin Dosing Interval for Ototoxicity (RADIO) Trial Comparing Chemoradiation (CRT) with Cisplatin Q3weekly to Weekly for Locally Advanced Squamous Cell Carcinoma of the Head and neck (LASCCHN),International Journal of Radiation Oncology Biology Physics,2024,10.1016/j.ijrobp.2024.01.027,https://experts.mcmaster.ca/display/publication3407188,2025-07-27T15:01:37.354072
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Bilateral Oophorectomy and All-Cause Mortality in Women WithBRCA1andBRCA2Sequence Variations,JAMA Oncology,2024,10.1001/jamaoncol.2023.6937,https://experts.mcmaster.ca/display/publication3402809,2025-07-27T15:01:37.354074
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,MRI Surveillance and Breast Cancer Mortality in Women WithBRCA1andBRCA2Sequence Variations,JAMA Oncology,2024,10.1001/jamaoncol.2023.6944,https://experts.mcmaster.ca/display/publication3402810,2025-07-27T15:01:37.354075
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis,British Journal of Cancer,2024,10.1038/s41416-023-02503-8,https://experts.mcmaster.ca/display/publication3321760,2025-07-27T15:01:37.354077
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with aBRCA1orBRCA2Mutation,Cancer Research Communications,2023,10.1158/2767-9764.crc-23-0223,https://experts.mcmaster.ca/display/publication3321761,2025-07-27T15:01:37.354078
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab,Oncologist,2023,10.1093/oncolo/oyad086,https://experts.mcmaster.ca/display/publication3126920,2025-07-27T15:01:37.354080
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation,Breast Cancer Research and Treatment,2023,10.1007/s10549-023-06991-3,https://experts.mcmaster.ca/display/publication3271987,2025-07-27T15:01:37.354086
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Detection of Macrotroponin in Patients Receiving Treatment for Breast Cancer,CJC OPEN,2023,10.1016/j.cjco.2023.05.010,https://experts.mcmaster.ca/display/publication3239585,2025-07-27T15:01:37.354087
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Re-examining content validity of the BREAST-Q more than a decade later to determine relevance and comprehensiveness,Journal of Patient-Reported Outcomes,2023,10.1186/s41687-023-00558-y,https://experts.mcmaster.ca/display/publication3097685,2025-07-27T15:01:37.354089
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,The risks of cancer in older women withBRCApathogenic variants: How far have we come?,Cancer,2023,10.1002/cncr.34615,https://experts.mcmaster.ca/display/publication2687518,2025-07-27T15:01:37.354090
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer",Annals of Oncology,2022,10.1016/j.annonc.2022.09.159,https://experts.mcmaster.ca/display/publication2498941,2025-07-27T15:01:37.354092
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,A Systematic Literature Review of Health Utility Values in Breast Cancer,Medical decision making,2022,10.1177/0272989x211065471,https://experts.mcmaster.ca/display/publication2165455,2025-07-27T15:01:37.354093
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Bilateral Oophorectomy and the Risk of Breast Cancer inBRCA1Mutation Carriers: A Reappraisal,"Cancer Epidemiology, Biomarkers and Prevention",2022,10.1158/1055-9965.epi-21-1196,https://experts.mcmaster.ca/display/publication2378440,2025-07-27T15:01:37.354095
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation,Gynecologic Oncology,2022,10.1016/j.ygyno.2022.01.014,https://experts.mcmaster.ca/display/publication2162409,2025-07-27T15:01:37.354096
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder alleleBRCA26174delT,Clinical Genetics,2022,10.1111/cge.14098,https://experts.mcmaster.ca/display/publication2166108,2025-07-27T15:01:37.354097
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial",The BMJ,2021,10.1136/bmj-2021-066588,https://experts.mcmaster.ca/display/publication2160251,2025-07-27T15:01:37.354099
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"ASO Visual Abstract: Development and Psychometric Validation of BREAST-Q Scales Measuring Cancer Worry, Fatigue, and Impact on Work",Annals of Surgical Oncology,2021,10.1245/s10434-021-10128-5,https://experts.mcmaster.ca/display/publication1980559,2025-07-27T15:01:37.354100
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,An international mixed methods study to develop a new preference-based measure for women with breast cancer: the BREAST-Q Utility module,BMC Women's Health,2021,10.1186/s12905-020-01125-z,https://experts.mcmaster.ca/display/publication1943692,2025-07-27T15:01:37.354102
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Development and Psychometric Validation of the BREAST-Q Sensation Module for Women Undergoing Post-Mastectomy Breast Reconstruction,Annals of Surgical Oncology,2021,10.1245/s10434-021-10094-y,https://experts.mcmaster.ca/display/publication1969762,2025-07-27T15:01:37.354103
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,An evaluation of memory and attention inBRCAmutation carriers using an online cognitive assessment tool,Cancer,2021,10.1002/cncr.33654,https://experts.mcmaster.ca/display/publication1978687,2025-07-27T15:01:37.354105
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Development and Psychometric Validation of the BREAST-Q Animation Deformity Scale for Women Undergoing an Implant-Based Breast Reconstruction After Mastectomy,Annals of Surgical Oncology,2021,10.1245/s10434-021-09619-2,https://experts.mcmaster.ca/display/publication1960716,2025-07-27T15:01:37.354106
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Abstract 878: Contraceptive use and ovarian cancer risk inBRCA1andBRCA2mutation carriers: A prospective cohort study,Cancer Research,2021,10.1158/1538-7445.am2021-878,https://experts.mcmaster.ca/display/publication3241541,2025-07-27T15:01:37.354108
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers,Breast Cancer Research and Treatment,2021,10.1007/s10549-020-06072-9,https://experts.mcmaster.ca/display/publication1957872,2025-07-27T15:01:37.354109
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Weight gain and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers,Molecular Genetics and Metabolism,2021,10.1016/s1096-7192(21)00626-0,https://experts.mcmaster.ca/display/publication3241542,2025-07-27T15:01:37.354111
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation,Gynecologic Oncology,2020,10.1016/j.ygyno.2020.09.037,https://experts.mcmaster.ca/display/publication1934740,2025-07-27T15:01:37.354112
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Evaluation of a novel strategy to implement exercise evidence into clinical practice in breast cancer care: protocol for the NEXT-BRCA randomised controlled trial,BMJ Open Sport and Exercise Medicine,2020,10.1136/bmjsem-2020-000922,https://experts.mcmaster.ca/display/publication1937566,2025-07-27T15:01:37.354114
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses,Oncology Nursing Forum,2020,10.1188/20.onf.e86-e106,https://experts.mcmaster.ca/display/publication1915738,2025-07-27T15:01:37.354115
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,CanPROS Scientific Conference 2019 Oral Abstracts,Current Oncology,2020,10.3747/co.27.6043,https://experts.mcmaster.ca/display/publication2776574,2025-07-27T15:01:37.354117
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module,BMJ Open,2020,10.1136/bmjopen-2019-034451,https://experts.mcmaster.ca/display/publication1686930,2025-07-27T15:01:37.354118
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy,Clinica Chimica Acta,2019,10.1016/j.cca.2019.04.083,https://experts.mcmaster.ca/display/publication1640435,2025-07-27T15:01:37.354119
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation,British Journal of Cancer,2019,10.1038/s41416-019-0446-1,https://experts.mcmaster.ca/display/publication1637366,2025-07-27T15:01:37.354121
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers,Breast Cancer Research and Treatment,2019,10.1007/s10549-019-05162-7,https://experts.mcmaster.ca/display/publication3266525,2025-07-27T15:01:37.354122
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab,Canadian Journal of Cardiology,2019,10.1016/j.cjca.2018.12.023,https://experts.mcmaster.ca/display/publication1634298,2025-07-27T15:01:37.354124
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer,Journal of Clinical Oncology,2018,10.1200/jco.18.00242,https://experts.mcmaster.ca/display/publication1593203,2025-07-27T15:01:37.354125
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Cancer prevention and screening in a BRCA2-positive male to female transgender patient,Breast Journal,2018,10.1111/tbj.13096,https://experts.mcmaster.ca/display/publication1570301,2025-07-27T15:01:37.354127
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk AmongBRCA1Mutation Carriers,JAMA Oncology,2018,10.1001/jamaoncol.2018.0211,https://experts.mcmaster.ca/display/publication1728762,2025-07-27T15:01:37.354128
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,The association between smoking and cancer incidence inBRCA1andBRCA2mutation carriers,International Journal of Cancer,2018,10.1002/ijc.31257,https://experts.mcmaster.ca/display/publication1733181,2025-07-27T15:01:37.354129
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE),Diabetes Care,2016,10.2337/dc15-1676,https://experts.mcmaster.ca/display/publication310793,2025-07-27T15:01:37.354131
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study,British Journal of Cancer,2016,10.1038/bjc.2016.58,https://experts.mcmaster.ca/display/publication962631,2025-07-27T15:01:37.354132
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario,Journal of Clinical Oncology,2016,10.1200/jco.2015.62.8503,https://experts.mcmaster.ca/display/publication863660,2025-07-27T15:01:37.354134
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation,Fertility and Sterility,2016,10.1016/j.fertnstert.2015.11.034,https://experts.mcmaster.ca/display/publication1733275,2025-07-27T15:01:37.354135
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses",Systematic Reviews,2015,10.1186/s13643-015-0099-y,https://experts.mcmaster.ca/display/publication1116734,2025-07-27T15:01:37.354136
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366,Diabetes Care,2014,10.2337/dc14-1220,https://experts.mcmaster.ca/display/publication886257,2025-07-27T15:01:37.354138
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366,Diabetes Care,2014,10.2337/dc14-1567,https://experts.mcmaster.ca/display/publication886255,2025-07-27T15:01:37.354139
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers,Breast Cancer Research and Treatment,2014,10.1007/s10549-014-3026-3,https://experts.mcmaster.ca/display/publication1733330,2025-07-27T15:01:37.354141
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia,Diabetes Care,2014,10.2337/dc13-1468,https://experts.mcmaster.ca/display/publication886271,2025-07-27T15:01:37.354142
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Adjuvant Chemotherapy for Breast Cancer in a Patient with Primary Autoimmune Neutropenia,Breast Cancer: Basic and Clinical Research,2013,10.4137/bcbcr.s10767,https://experts.mcmaster.ca/display/publication916554,2025-07-27T15:01:37.354144
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Development and validation of a brief screening instrument for psychosocial risk associated with genetic testing: a pan-Canadian cohort study,BMJ Open,2013,10.1136/bmjopen-2012-002227,https://experts.mcmaster.ca/display/publication962627,2025-07-27T15:01:37.354145
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer,Breast Cancer Research and Treatment,2012,10.1007/s10549-012-2205-3,https://experts.mcmaster.ca/display/publication276908,2025-07-27T15:01:37.354146
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia,New England Journal of Medicine,2012,10.1056/nejmoa1203858,https://experts.mcmaster.ca/display/publication886287,2025-07-27T15:01:37.354148
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia,New England Journal of Medicine,2012,10.1056/nejmoa1203859,https://experts.mcmaster.ca/display/publication886288,2025-07-27T15:01:37.354149
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,A fatal case ofPneumocystis jiroveciipneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab,Journal of Oncology Pharmacy Practice,2012,10.1177/1078155211412991,https://experts.mcmaster.ca/display/publication1116737,2025-07-27T15:01:37.354151
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients,Journal of Oncology Pharmacy Practice,2012,10.1177/1078155211429384,https://experts.mcmaster.ca/display/publication1116736,2025-07-27T15:01:37.354152
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers,Breast Cancer Research,2012,10.1186/bcr3138,https://experts.mcmaster.ca/display/publication1733406,2025-07-27T15:01:37.354153
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial,The Lancet Oncology,2012,10.1016/s1470-2045(11)70389-8,https://experts.mcmaster.ca/display/publication801182,2025-07-27T15:01:37.354155
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Diabetes and breast cancer among women withBRCA1andBRCA2mutations,Cancer,2011,10.1002/cncr.25595,https://experts.mcmaster.ca/display/publication962663,2025-07-27T15:01:37.354160
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (2001–2009),Journal of the National Cancer Institute,2011,10.1093/jnci/djq508,https://experts.mcmaster.ca/display/publication1521469,2025-07-27T15:01:37.354161
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Willingness of breast cancer survivors to participate in a randomized controlled trial of digital mammography with or without MRI as breast cancer surveillance: A feasibility study,Breast,2011,10.1016/j.breast.2010.08.006,https://experts.mcmaster.ca/display/publication962639,2025-07-27T15:01:37.354163
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors",Journal of Clinical Oncology,2010,10.1200/jco.2010.29.9230,https://experts.mcmaster.ca/display/publication962657,2025-07-27T15:01:37.354164
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Does family history predict the age at onset of new breast cancers inBRCA1andBRCA2mutation‐positive families?,Clinical Genetics,2010,10.1111/j.1399-0004.2009.01328.x,https://experts.mcmaster.ca/display/publication962672,2025-07-27T15:01:37.354166
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Prognosis of BRCA-associated breast cancer: a summary of evidence,Breast Cancer Research and Treatment,2010,10.1007/s10549-009-0566-z,https://experts.mcmaster.ca/display/publication962660,2025-07-27T15:01:37.354167
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer,Nature Reviews Clinical Oncology,2009,10.1038/nrclinonc.2009.116,https://experts.mcmaster.ca/display/publication584717,2025-07-27T15:01:37.354169
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study,Journal of Clinical Oncology,2009,10.1200/jco.2009.27.15_suppl.1534,https://experts.mcmaster.ca/display/publication3241543,2025-07-27T15:01:37.354170
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Selecting a BRCA risk assessment model for use in a familial cancer clinic,BMC Medical Genetics,2008,10.1186/1471-2350-9-116,https://experts.mcmaster.ca/display/publication1750355,2025-07-27T15:01:37.354171
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials,Journal of Clinical Oncology,2008,10.1200/jco.2007.15.3726,https://experts.mcmaster.ca/display/publication1567310,2025-07-27T15:01:37.354173
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Treating dural metastases mimicking intracranial hypotension.,The Journal of Supportive Oncology,2007,,https://experts.mcmaster.ca/display/publication1116741,2025-07-27T15:01:37.354174
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"Responsiveness to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer",Quality of Life Research,2007,10.1007/s11136-007-9253-x,https://experts.mcmaster.ca/display/publication1750352,2025-07-27T15:01:37.354176
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"Responsiveness to change to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer",Quality of Life Research,2007,10.1007/s11136-007-9208-2,https://experts.mcmaster.ca/display/publication1750351,2025-07-27T15:01:37.354177
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,"Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples",Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.1024,https://experts.mcmaster.ca/display/publication3241547,2025-07-27T15:01:37.354179
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Descriptive study on the lost productivity in breast cancer patients,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.6542,https://experts.mcmaster.ca/display/publication3241545,2025-07-27T15:01:37.354181
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.17042,https://experts.mcmaster.ca/display/publication3241546,2025-07-27T15:01:37.354182
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Three methods for minimally important difference: no relationship was found with the net proportion of patients improving,Journal of Clinical Epidemiology,2007,10.1016/j.jclinepi.2006.08.006,https://experts.mcmaster.ca/display/publication1750353,2025-07-27T15:01:37.354183
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review,Clinical Therapeutics,2007,10.1016/j.clinthera.2007.02.006,https://experts.mcmaster.ca/display/publication794870,2025-07-27T15:01:37.354185
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review.,Clinical Therapeutics,2007,10.1016/j.clinthera.2007.02.006,https://experts.mcmaster.ca/display/publication1064627,2025-07-27T15:01:37.354186
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Management of the BRCA Mutation Carrier or High-Risk Patient,Clinics in Plastic Surgery,2007,10.1016/j.cps.2006.11.010,https://experts.mcmaster.ca/display/publication1750354,2025-07-27T15:01:37.354188
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,A comparison of BRCA1 and BRCA2 risk assessment models,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.10034,https://experts.mcmaster.ca/display/publication3241544,2025-07-27T15:01:37.354189
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG),Annals of Oncology,2006,10.1093/annonc/mdl056,https://experts.mcmaster.ca/display/publication744060,2025-07-27T15:01:37.354190
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Pharmacoeconomics of Systemic Therapies for Lung Cancer,Treatments in Respiratory Medicine,2006,10.2165/00151829-200605020-00006,https://experts.mcmaster.ca/display/publication1116743,2025-07-27T15:01:37.354192
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells,Leukemia,2005,10.1038/sj.leu.2403773,https://experts.mcmaster.ca/display/publication962632,2025-07-27T15:01:37.354193
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures,Journal of Clinical Oncology,2005,10.1200/jco.2005.23.16_suppl.8035,https://experts.mcmaster.ca/display/publication3241548,2025-07-27T15:01:37.354195
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables,Journal of Clinical Oncology,2004,10.1200/jco.2004.12.091,https://experts.mcmaster.ca/display/publication1567182,2025-07-27T15:01:37.354196
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data,Journal of Clinical Oncology,2003,10.1200/jco.2003.04.080,https://experts.mcmaster.ca/display/publication507445,2025-07-27T15:01:37.354197
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Clinical manifestations associated with the aberrant expression of the soluble granulocyte–macrophage colony‐stimulating factor receptor in patients presenting with haematological malignancies,British Journal of Haematology,2003,10.1046/j.1365-2141.2003.04235.x,https://experts.mcmaster.ca/display/publication962654,2025-07-27T15:01:37.354199
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Review: breastfeeding is associated with reduced risk of breast cancer,BMJ Evidence-Based Medicine,2003,10.1136/ebm.8.2.63,https://experts.mcmaster.ca/display/publication1750350,2025-07-27T15:01:37.354200
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer--Taking Stock,Journal of the National Cancer Institute,2003,10.1093/jnci/95.4.263,https://experts.mcmaster.ca/display/publication1750347,2025-07-27T15:01:37.354206
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Decreased bone mineral density is common after autologous blood or marrow transplantation,Bone Marrow Transplantation,2001,10.1038/sj.bmt.1703149,https://experts.mcmaster.ca/display/publication698170,2025-07-27T15:01:37.354207
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis,Cancer,2001,10.1002/1097-0142(20010701)92:1<23::aid-cncr1287>3.0.co;2-y,https://experts.mcmaster.ca/display/publication962676,2025-07-27T15:01:37.354209
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review.,Seminars in Oncology,2000,,https://experts.mcmaster.ca/display/publication1116749,2025-07-27T15:01:37.354210
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer,Journal of the National Cancer Institute,2000,10.1093/jnci/92.16.1321,https://experts.mcmaster.ca/display/publication962691,2025-07-27T15:01:37.354212
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Economic Issues in Lung Cancer,Seminars in Respiratory and Critical Care Medicine,2000,10.1055/s-2000-9400,https://experts.mcmaster.ca/display/publication962684,2025-07-27T15:01:37.354213
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Economic issues in lung cancer,Seminars in Respiratory and Critical Care Medicine,2000,10.1055/s-2000-9400,https://experts.mcmaster.ca/display/publication1750349,2025-07-27T15:01:37.354215
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Aortic dissection and turner’s syndrome: case report and review of the literature,Journal of Emergency Medicine,1998,10.1016/s0736-4679(98)00041-9,https://experts.mcmaster.ca/display/publication1116752,2025-07-27T15:01:37.354216
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,2 ‐Chloro‐deoxyadenosine therapy for giant lymph node hyperplasia,British Journal of Haematology,1995,10.1111/j.1365-2141.1995.tb05366.x,https://experts.mcmaster.ca/display/publication962687,2025-07-27T15:01:37.354217
Louise Bordeleau,bordeleaul@HHSC.CA,journal_articles,Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre,Genetic Syndromes and Gene Therapy,,10.4172/2157-7412.1000156,https://experts.mcmaster.ca/display/publication2552563,2025-07-27T15:01:37.354219
Louise Bordeleau,bordeleaul@HHSC.CA,chapters,"Medical, Psychosocial, and Health-Related Quality of Life Issues in Breast Cancer Survivors",,2007,10.1007/978-0-387-68265-5_11,https://experts.mcmaster.ca/display/publication1750348,2025-07-27T15:01:37.354221
Louise Bordeleau,bordeleaul@HHSC.CA,chapters,"Medical, Psychosocial, and Health-Related Quality of Life Issues in Breast Cancer Survivors",,2006,10.1007/0-387-31056-8_106,https://experts.mcmaster.ca/display/publication1750346,2025-07-27T15:01:37.354222
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,eP160: Bilateral oophorectomy and the risk of breast cancer in women with a pathogenic variant in BRCA1: A reappraisal,Genetics in Medicine,2022,10.1016/j.gim.2022.01.196,https://experts.mcmaster.ca/display/publication2189000,2025-07-27T15:01:37.354224
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,"Development and Psychometric Validation of BREAST-Q Scales Measuring Cancer Worry, Fatigue, and Impact on Work",Annals of Surgical Oncology,2021,10.1245/s10434-021-10090-2,https://experts.mcmaster.ca/display/publication1962336,2025-07-27T15:01:37.354225
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Weight Gain and the Risk of Ovarian Cancer inBRCA1andBRCA2Mutation Carriers,"Cancer Epidemiology, Biomarkers and Prevention",2021,10.1158/1055-9965.epi-21-0296,https://experts.mcmaster.ca/display/publication1970097,2025-07-27T15:01:37.354227
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,"Development of LYMPH-Q upper extremity scales measuring worry, work impact, and burden of conservative treatments",Quality of Life Research,2021,,https://experts.mcmaster.ca/display/publication2145780,2025-07-27T15:01:37.354228
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study.,Cancer Research,2021,,https://experts.mcmaster.ca/display/publication2123537,2025-07-27T15:01:37.354230
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Examining content validity of BREAST-Q a decade later to determine relevance and comprehensiveness,Quality of Life Research,2019,,https://experts.mcmaster.ca/display/publication1669609,2025-07-27T15:01:37.354232
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,"Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)",Cancer Research,2019,10.1158/1538-7445.sabcs18-pd1-10,https://experts.mcmaster.ca/display/publication1660320,2025-07-27T15:01:37.354233
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Assessment of myocardial injury early after initiation of treatment in breast cancer patients using the Beckman Coulter and Abbott Diagnostics high-sensitivity cardiac troponin I tests,Clinical Biochemistry,2018,,https://experts.mcmaster.ca/display/publication1604041,2025-07-27T15:01:37.354234
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Development of health-state classification system for a new breast cancer-specific preference-based measure: the BREAST-Q-U,Quality of Life Research,2018,,https://experts.mcmaster.ca/display/publication1600525,2025-07-27T15:01:37.354236
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Abstract P5-20-17: Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study,Cancer Research,2018,10.1158/1538-7445.sabcs17-p5-20-17,https://experts.mcmaster.ca/display/publication2579278,2025-07-27T15:01:37.354237
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study,Cancer Research,2018,,https://experts.mcmaster.ca/display/publication1504350,2025-07-27T15:01:37.354239
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC).,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.15_suppl.1073,https://experts.mcmaster.ca/display/publication1470500,2025-07-27T15:01:37.354240
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,"The feasibility, acceptability and safety of Molecular Breast Imaging (MBI) using a breast specific gamma camera and 99mTc-sestamibi in patients with a high risk of breast cancer",European Journal of Nuclear Medicine and Molecular Imaging,2013,,https://experts.mcmaster.ca/display/publication310589,2025-07-27T15:01:37.354242
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial,Diabetes,2013,,https://experts.mcmaster.ca/display/publication962637,2025-07-27T15:01:37.354243
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial,Diabetes,2013,,https://experts.mcmaster.ca/display/publication962638,2025-07-27T15:01:37.354244
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,"A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer.",Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.9020,https://experts.mcmaster.ca/display/publication310574,2025-07-27T15:01:37.354246
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial.,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.1504,https://experts.mcmaster.ca/display/publication962643,2025-07-27T15:01:37.354247
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.tps108,https://experts.mcmaster.ca/display/publication195016,2025-07-27T15:01:37.354249
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Absence of Histologic Differences between Benign Breast Tissue from BRCA Carriers and Controls Despite Differential Gene Expression,Modern Pathology,2011,,https://experts.mcmaster.ca/display/publication962626,2025-07-27T15:01:37.354250
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Absence of Histologic Differences between Benign Breast Tissue from BRCA Carriers and Controls Despite Differential Gene Expression,Laboratory Investigation,2011,,https://experts.mcmaster.ca/display/publication962628,2025-07-27T15:01:37.354252
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Abstract P2-11-01: Molecular Profiling Identifies Differentially Expressed Genes between Normal Breast Tissue fromBRCACarriers and Women at Population Risk,Cancer Research,2010,10.1158/0008-5472.sabcs10-p2-11-01,https://experts.mcmaster.ca/display/publication962634,2025-07-27T15:01:37.354253
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.9023,https://experts.mcmaster.ca/display/publication795172,2025-07-27T15:01:37.354255
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study,Journal of Clinical Oncology,2009,,https://experts.mcmaster.ca/display/publication962675,2025-07-27T15:01:37.354256
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,"Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.",Anticancer Research,2009,,https://experts.mcmaster.ca/display/publication962671,2025-07-27T15:01:37.354257
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,A comparison of internet-based models assessing the likelihood of aBRCAmutation,Journal of Clinical Oncology,2008,10.1200/jco.2008.26.15_suppl.22051,https://experts.mcmaster.ca/display/publication962640,2025-07-27T15:01:37.354259
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Health preference instruments in a breast cancer population: Is there a ceiling effect when compared to the quality-of-life instruments?,Journal of Clinical Oncology,2008,10.1200/jco.2008.26.15_suppl.6597,https://experts.mcmaster.ca/display/publication962625,2025-07-27T15:01:37.354261
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,"Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples",Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication3266527,2025-07-27T15:01:37.354262
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Descriptive study on the lost productivity in breast cancer patients,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication3266526,2025-07-27T15:01:37.354264
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1623570,2025-07-27T15:01:37.354265
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,A comparison of BRCA1 and BRCA2 risk assessment models.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication962635,2025-07-27T15:01:37.354267
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Evaluating the performance of risk assessment models in BRCA1 and BRCA2 mutation detection.,Breast Cancer Research and Treatment,2006,,https://experts.mcmaster.ca/display/publication962641,2025-07-27T15:01:37.354268
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures.,Journal of Clinical Oncology,2005,,https://experts.mcmaster.ca/display/publication962636,2025-07-27T15:01:37.354269
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,"Health related quality of life (HRQOL) and psychosocial status at diagnosis are not associated with disease-free or overall survival (DFS or OS) in T1-3, N0-1, M0 breast cancer (BC).",Breast Cancer Research and Treatment,2002,,https://experts.mcmaster.ca/display/publication1567200,2025-07-27T15:01:37.354271
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,5-Aza-2 '-deoxycytidine (5-Aza-2-Cdr) reverses CpG methylation of the retinoic acid receptor beta (RAR beta) promoter and restores retinoid responsiveness in non M3 acute myelogenous leukemia (AML) blasts.,Blood,2001,,https://experts.mcmaster.ca/display/publication3266528,2025-07-27T15:01:37.354272
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Phase II study of repetitive mini-transplant using a novel dose-intense salvage chemotherapy regimen (M-DHAP) followed by high dose therapy (HDT) and autologous stem cell transplant (ASCT) in relapsed aggressive non-Hodgkin lymphoma (NHL).,Blood,2001,,https://experts.mcmaster.ca/display/publication898714,2025-07-27T15:01:37.354274
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Molecular diagnostics in follicular non-Hodgkin's lymphoma: A review,Seminars in Oncology,2000,10.1053/sonc.2000.20440,https://experts.mcmaster.ca/display/publication962659,2025-07-27T15:01:37.354275
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Decreased bone mineral density after autologous blood and marrow transplantation(ABMT).,Blood,1999,,https://experts.mcmaster.ca/display/publication962661,2025-07-27T15:01:37.354277
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,In vivo purging with rituxan prior to stem cell collection is associated with persistant molecular evidence of T(14;18) that often disappears post transplant in patients with follicular lymphoma.,Blood,1999,,https://experts.mcmaster.ca/display/publication898743,2025-07-27T15:01:37.354278
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Low-grade lymphoma: A prospective multicenter evaluation of clinical and biologic prognostic factors.,Blood,1999,,https://experts.mcmaster.ca/display/publication898744,2025-07-27T15:01:37.354279
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Outpatient autologous hematopoietic stem cell (HSCT) transplantation following short course VAD in multiple myeloma.,Blood,1998,,https://experts.mcmaster.ca/display/publication962655,2025-07-27T15:01:37.354281
Louise Bordeleau,bordeleaul@HHSC.CA,conferences,Incremental cost effectiveness of maintaining dose intensity with G-CSF as primary therapy of intermediate grade non-Hodgkin's lymphoma.,Blood,1997,,https://experts.mcmaster.ca/display/publication962669,2025-07-27T15:01:37.354282
Louise Bordeleau,bordeleaul@HHSC.CA,other,Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.c.6951875,https://experts.mcmaster.ca/display/publication3323995,2025-07-27T15:01:37.354284
Louise Bordeleau,bordeleaul@HHSC.CA,other,Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.c.6951875.v1,https://experts.mcmaster.ca/display/publication3323999,2025-07-27T15:01:37.354285
Louise Bordeleau,bordeleaul@HHSC.CA,other,FIGURE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649710.v1,https://experts.mcmaster.ca/display/publication3323993,2025-07-27T15:01:37.354287
Louise Bordeleau,bordeleaul@HHSC.CA,other,FIGURE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649710,https://experts.mcmaster.ca/display/publication3324012,2025-07-27T15:01:37.354288
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649707,https://experts.mcmaster.ca/display/publication3323992,2025-07-27T15:01:37.354290
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649707.v1,https://experts.mcmaster.ca/display/publication3323998,2025-07-27T15:01:37.354291
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649704.v1,https://experts.mcmaster.ca/display/publication3323991,2025-07-27T15:01:37.354293
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649704,https://experts.mcmaster.ca/display/publication3324004,2025-07-27T15:01:37.354295
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649701,https://experts.mcmaster.ca/display/publication3324006,2025-07-27T15:01:37.354296
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649701.v1,https://experts.mcmaster.ca/display/publication3324008,2025-07-27T15:01:37.354298
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649698.v1,https://experts.mcmaster.ca/display/publication3324007,2025-07-27T15:01:37.354299
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649698,https://experts.mcmaster.ca/display/publication3324009,2025-07-27T15:01:37.354300
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 5 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649695.v1,https://experts.mcmaster.ca/display/publication3323988,2025-07-27T15:01:37.354302
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 5 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649695,https://experts.mcmaster.ca/display/publication3324003,2025-07-27T15:01:37.354303
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 6 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649692.v1,https://experts.mcmaster.ca/display/publication3323989,2025-07-27T15:01:37.354305
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 6 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649692,https://experts.mcmaster.ca/display/publication3323997,2025-07-27T15:01:37.354306
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 7 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649689,https://experts.mcmaster.ca/display/publication3324005,2025-07-27T15:01:37.354307
Louise Bordeleau,bordeleaul@HHSC.CA,other,Supplementary Table 7 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649689.v1,https://experts.mcmaster.ca/display/publication3324010,2025-07-27T15:01:37.354309
Louise Bordeleau,bordeleaul@HHSC.CA,other,TABLE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649686.v1,https://experts.mcmaster.ca/display/publication3323994,2025-07-27T15:01:37.354310
Louise Bordeleau,bordeleaul@HHSC.CA,other,TABLE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649686,https://experts.mcmaster.ca/display/publication3324001,2025-07-27T15:01:37.354312
Louise Bordeleau,bordeleaul@HHSC.CA,other,TABLE 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649683.v1,https://experts.mcmaster.ca/display/publication3323990,2025-07-27T15:01:37.354313
Louise Bordeleau,bordeleaul@HHSC.CA,other,TABLE 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649683,https://experts.mcmaster.ca/display/publication3324000,2025-07-27T15:01:37.354315
Louise Bordeleau,bordeleaul@HHSC.CA,other,TABLE 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649680.v1,https://experts.mcmaster.ca/display/publication3324002,2025-07-27T15:01:37.354316
Louise Bordeleau,bordeleaul@HHSC.CA,other,TABLE 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649680,https://experts.mcmaster.ca/display/publication3324011,2025-07-27T15:01:37.354317
Louise Bordeleau,bordeleaul@HHSC.CA,other,TABLE 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649677.v1,https://experts.mcmaster.ca/display/publication3323996,2025-07-27T15:01:37.354319
Louise Bordeleau,bordeleaul@HHSC.CA,other,TABLE 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation,,2023,10.1158/2767-9764.24649677,https://experts.mcmaster.ca/display/publication3324013,2025-07-27T15:01:37.354324
